From Lab to Launch: Commercializing Gene Therapies for Rare Diseases with Rocket Pharma’s Carlos Martin

Xtalks Life Science Podcast

In this episode, Ayesha spoke with Carlos Martin, MBA, chief commercial operations and revenue officer at Rocket Pharmaceuticals, a company developing gene therapy cures for rare diseases through innovative science and platforms.

Carlos joined Rocket in April 2021 and established the company’s early commercial strategy and infrastructure as Chief Commercial Officer.

Prior to joining Rocket, Carlos was the US Commercial Head of Advanced Accelerator Applications (AAA), a Novartis Oncology Company. His responsibilities included leading commercial strategy and new product launches as well as transforming their go-to-market model.

Carlos brings in-depth background and experience globally and locally in commercial strategy and operations across a wide range of modalities and disease areas, including oncology, cardiovascular, metabolism and complex therapeutics.

Carlos has a bachelor’s degree in economics from ESADE & the Polytechnic University of Barcelona, Spain and an MBA from the Thunderbird School of Global Management at Arizona State University.

Tune in to hear from Carlos about the challenges and opportunities in the commercialization of gene therapies for rare diseases.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured